ASCO20 – PROSPER Trial Data – Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC)

Dr. Andrew Krivoshik, SVP, and Oncology Therapeutic Area Head at Astellas Pharma US discusses the overall survival findings from the Phase 3 PROSPER trial in men with non-metastatic castration-resistant prostate cancer (nmCRPC) that was published in the online “New England Journal of Medicine” (NEJM) and also presented during the 2020 American Society of Clinical Oncology (ASCO20) Annual Meeting (Abstract #5515). 

Andrew P. Krivoshik began his career in academic medicine, often balancing time in the lab with time seeing patients in the clinic. Now Senior Vice President and Oncology Therapeutic Head of Astellas Pharma US, his career is focused on pharmaceutical development to help serve more patients and make a greater impact in their care. Dr. Krivoshik has expertise in global clinical development including implementing novel and innovative clinical trial designs, is a subject matter expert and primary author of clinical protocols, investigator brochures, and regulatory submissions spanning the life cycle of clinical development, and is an invited speaker and session chair at international scientific congresses.

Liked it? Take a second to support healthprofessionalradio on Patreon!

0 Comments

Leave a Reply

You must be logged in to post a comment.